USPTO Examiner MONTANARI DAVID A - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18658343UNIVERSAL DONOR STEM CELLS AND RELATED METHODSMay 2024August 2025Allow1511YesNo
18658385UNIVERSAL DONOR STEM CELLS AND RELATED METHODSMay 2024February 2026Allow2121YesNo
18434746EXPRESSION CASSETTE CONTAINING OVERLAPPING OPEN READING FRAMES AND APPLICATIONFebruary 2024July 2025Allow1721YesNo
18371839FUNCTIONAL FELINE PANCREATIC CELLS FROM ADIPOSE TISSUESeptember 2023December 2025Allow2611YesNo
18472072UNIVERSAL DONOR CELLS AND RELATED METHODSSeptember 2023November 2025Allow2610NoNo
18278100METHODS FOR CULTURING AND DIFFERENTIATING PLURIPOTENT CELLS INTO PROGENITOR OR MATURE MUSCLE CELLS AND COMPOSITION COMPRISING SAID CELLSAugust 2023July 2025Allow2321YesNo
18448674Methods and Culture Substrates for Controlled Induction of Biomimetic Neural Tissues Comprising Singular Rosette StructuresAugust 2023September 2025Allow2510YesNo
18271677SIMULATION METHOD FOR CHRONIC ATROPHIC GASTRITIS (CAG) LESION AND IDENTIFICATION METHOD FOR MOUSE MODELINGJuly 2023May 2025Abandon2220NoNo
18340537COMPOSITIONS AND METHODS FOR ORGANOID GENERATION AND DISEASE MODELINGJune 2023November 2025Abandon2911NoNo
18210821DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLSJune 2023May 2025Abandon2310NoNo
18322105ACCELERATION OF STEM CELL DIFFERENTIATIONMay 2023July 2025Abandon2610NoNo
18321400Chimeric Antigen ReceptorMay 2023July 2025Abandon2601NoNo
18319677METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIESMay 2023June 2025Allow2510YesNo
18317465METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNASMay 2023January 2026Allow3211NoNo
18128994COMPOSITIONS AND METHODS FOR MAMMALIAN GENETICS AND USES THEREOFMarch 2023November 2025Allow3211YesNo
18119405CANCER DETECTION METHOD USING SENSE OF SMELL OF NEMATODEMarch 2023September 2025Allow3011YesNo
18179814SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITYMarch 2023October 2023Allow710NoNo
18115283Methods of Producing Specialized Cardio-Like Cells from Stem CellsFebruary 2023February 2025Abandon2310NoNo
18110276HUMANIZED LIGHT CHAIN MICEFebruary 2023June 2025Allow2810NoNo
18166503HLA-F-MODIFIED CELLS AND METHODSFebruary 2023April 2024Allow1421YesNo
18106972Retroviral VectorFebruary 2023January 2025Allow2341YesYes
18106039OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATIONFebruary 2023October 2025Allow3220NoNo
18160825TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORSJanuary 2023June 2025Allow2910NoNo
18099852METHODS FOR MAKING INSULIN IN VIVOJanuary 2023June 2025Allow2910YesNo
18016866EXPRESSION CASSETTE FOR EXPRESSING GENE COMPRISING OVERLAPPING OPEN READING FRAMES IN INSECT CELL AND APPLICATION THEREOFJanuary 2023August 2025Allow3131YesNo
18151369UNIVERSAL DONOR CELLSJanuary 2023September 2025Allow3211YesNo
18147554HEMATOPOIETIC STEM AND PROGENITOR CELLS DERIVED FROM HEMOGENIC ENDOTHELIAL CELLS BY EPISOMAL PLASMID GENE TRANSFERDecember 2022July 2024Allow1820YesNo
18083912CELLULAR MICROCOMPARTMENT AND PREPARATION PROCESSESDecember 2022July 2024Allow1910YesNo
18062252COMPOSITION FOR INCREASING EXPRESSION OF BLOOD COAGULATION FACTOR GENE, COMPRISING CORE-SHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENTDecember 2022March 2026Abandon3901NoNo
17993667UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022March 2024Allow1611YesNo
17993659UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022October 2024Allow2311NoNo
17993674UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022March 2024Allow1611YesNo
17993680UNIVERSAL DONOR STEM CELLS AND RELATED METHODSNovember 2022March 2024Allow1611YesNo
17985746METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLSNovember 2022February 2024Abandon1520YesNo
18054860METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLSNovember 2022January 2026Allow3850YesYes
17969254GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH COMMON LIGHT CHAIN IMMUNOGLOBULIN LOCUSOctober 2022March 2024Allow2721YesNo
17968675DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLSOctober 2022March 2025Abandon2910NoNo
17959203PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAMEOctober 2022October 2025Abandon3621NoNo
17944937TRANSGENIC ANIMAL PHENOTYPING PLATFORM AND USES THEREOFSeptember 2022July 2025Allow3411YesNo
17818669UNIVERSAL DONOR CELLSAugust 2022May 2025Allow3311NoNo
17841117NUCLEIC ACID CONSTRUCTS ENCODING CHIMERIC NK RECEPTOR, CELLS CONTAINING, AND THERAPEUTIC USE THEREOFJune 2022August 2023Allow1411YesNo
17832162METHODSJune 2022January 2024Allow1910YesNo
17832225Method for Depleting Malignant T-CellsJune 2022September 2023Allow1510YesNo
17832371Method for Depleting Malignant T-CellsJune 2022September 2023Allow1510YesNo
17832341METHODSJune 2022January 2024Allow1910YesNo
17830739METHODS FOR LOWERING BLOOD GLUCOSEJune 2022October 2025Allow4120YesNo
17827142DETECTION OF A DEFECT ON HLA-E RESTRICTED CD8+ T REGULATORY CELLSMay 2022July 2023Allow1421YesNo
17752505METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOFMay 2022February 2026Allow4521YesNo
17749735DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO SINGLE HORMONAL INSULIN POSITIVE CELLSMay 2022September 2024Allow2810NoNo
17748683CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCERMay 2022March 2025Allow3411YesNo
17728790Methods and Systems for Guide RNA Design and UseApril 2022May 2023Allow1211YesNo
17725478TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORSApril 2022November 2022Allow710NoNo
17724907METHOD FOR INDUCING ANTIGEN SPECIFIC CD8 POSITIVE T CELLSApril 2022April 2025Allow3610NoNo
17769456GROWTH INHIBITORApril 2022October 2025Allow4211YesNo
17767524Epicardial Delivery of Gene TherapyApril 2022December 2025Abandon4410NoNo
17715889METHODS AND MATERIALS FOR HEMATOENDOTHELIAL DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS UNDER DEFINED CONDITIONSApril 2022December 2025Allow4421NoNo
17706272COMPOSITIONS AND METHODS FOR ORGANOID GENERATION AND DISEASE MODELINGMarch 2022February 2023Allow1011NoNo
17704429USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLSMarch 2022December 2025Allow4511YesNo
17685586DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAMEMarch 2022January 2025Abandon3501NoNo
17679128HLA-F-MODIFIED CELLS AND METHODSFebruary 2022September 2025Allow4221YesNo
17671571DUAL STRAND NUCLEIC ACID-GUIDED NICKASE EDITINGFebruary 2022June 2023Allow1620NoNo
17579169REPROGRAMMING METHODS AND CELL CULTURE PLATFORMSJanuary 2022January 2026Allow4721YesYes
17573552METHODS OF USING PDX1-POSITIVE PANCREATIC ENDODERM CELLS AND ENDOCRINE PRECURSOR CELLSJanuary 2022August 2024Allow3120YesNo
17569896Methods and Compositions for Treatment of Disorders and Diseases Involving RDH12January 2022May 2025Allow4070YesYes
17566924UNIVERSAL DONOR CELLSDecember 2021October 2022Allow1011YesNo
17559140RAAV WITH CHEMICALLY MODIFIED CAPSIDDecember 2021July 2024Abandon3111NoNo
17619614COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOFDecember 2021January 2026Allow4911NoNo
17550945GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICEDecember 2021May 2025Allow4111YesNo
17541818SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITYDecember 2021February 2023Allow1421YesNo
17532075A Lentivirus Packaging System Comprising a Synthetic Positive Feedback LoopNovember 2021September 2024Allow3411YesNo
17514609SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAMEOctober 2021December 2024Abandon3810NoNo
17499569COLONY FORMING MEDIUM AND USE THEREOFOctober 2021October 2025Allow4821YesNo
17497927UNIVERSAL DONOR STEM CELLS AND RELATED METHODSOctober 2021June 2022Allow810NoNo
17489308PROTECTED GUIDE RNAS (PGRNAS)September 2021October 2025Allow4921YesNo
17474393METHODS, COMPOSITIONS AND SYSTEMS FOR PRODUCTION OF RECOMBINANT SPIDER SILK POLYPEPTIDESSeptember 2021June 2025Allow4511NoNo
17472263STEM CELL DERIVED ISLET DIFFERENTIATIONSeptember 2021September 2022Allow1220YesNo
17468225T Cell Modification and Use ThereofSeptember 2021July 2024Allow3411YesNo
17390673TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORSJuly 2021January 2022Allow610YesNo
17383760UNIVERSAL DONOR CELLSJuly 2021July 2022Allow1211YesNo
17375293METHODS FOR THE IN VITRO MANUFACTURE OF GASTRIC FUNDUS TISSUE AND COMPOSITIONS RELATED TO SAMEJuly 2021September 2025Abandon5030NoNo
17375368ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROMJuly 2021December 2024Abandon4120NoNo
17369525GENE THERAPY FOR OCULAR DISORDERSJuly 2021April 2025Allow4511YesNo
17341220NUTRIENT MEDIA FOR THE PRODUCTION OF SLAUGHTER-FREE MEATJune 2021February 2024Allow3341YesNo
17306537COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAMEMay 2021March 2024Abandon3501NoNo
17245405METHODS AND COMPOSITIONS FOR ASSESSING CRISPR/CAS-MEDIATED DISRUPTION OR EXCISION AND CRISPR/CAS-INDUCED RECOMBINATION WITH AN EXOGENOUS DONOR NUCLEIC ACID IN VIVOApril 2021March 2024Abandon3501NoNo
17242937METHODS OF CANCER IMMUNOTHERAPYApril 2021October 2025Abandon5431NoNo
17241947CANCER DETECTION METHOD USING SENSE OF SMELL OF NEMATODEApril 2021March 2026Allow5941YesNo
17241032ADENO-ASSOCIATED VARIANTS, FORMULATIONS AND METHODS FOR PULMONARY DELIVERYApril 2021September 2022Allow1730YesNo
17288442New Tools for Improving Gene Therapy and Use ThereofApril 2021October 2024Abandon4201NoNo
17230354Compositions and Methods for Correction of Heritable Ocular DiseaseApril 2021November 2025Allow5511YesNo
17200301TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORSMarch 2021May 2021Allow200YesNo
17172581RAAV WITH CHEMICALLY MODIFIED CAPSIDFebruary 2021November 2021Allow911YesNo
17168774METHODS FOR EXPRESSING PROTEINS IN AXONSFebruary 2021January 2024Allow3510NoNo
17160087DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORSJanuary 2021May 2024Abandon3911NoNo
16958630ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOFJanuary 2021March 2025Allow5711YesNo
17148556UNIVERSAL DONOR STEM CELLS AND RELATED METHODSJanuary 2021October 2022Allow2121YesNo
17148425GENOME-MODIFIED RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORSJanuary 2021July 2024Abandon4211NoNo
17141327COMPOSITIONS AND METHODS FOR TREATING TYPE 1 AND TYPE 2 DIABETES AND RELATED DISORDERSJanuary 2021September 2024Allow4511YesNo
17253956ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MUSCLE SPECIFIC MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHYDecember 2020March 2025Allow5121YesNo
17124667A method of cell therapyDecember 2020January 2025Allow4911YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONTANARI, DAVID A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
7
(53.8%)
Examiner Reversed
6
(46.2%)
Reversal Percentile
68.4%
Higher than average

What This Means

With a 46.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
124
Allowed After Appeal Filing
37
(29.8%)
Not Allowed After Appeal Filing
87
(70.2%)
Filing Benefit Percentile
45.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 29.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MONTANARI, DAVID A - Prosecution Strategy Guide

Executive Summary

Examiner MONTANARI, DAVID A works in Art Unit 1632 and has examined 845 patent applications in our dataset. With an allowance rate of 58.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner MONTANARI, DAVID A's allowance rate of 58.1% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MONTANARI, DAVID A receive 2.44 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MONTANARI, DAVID A is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +52.5% benefit to allowance rate for applications examined by MONTANARI, DAVID A. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.2% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 46.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 41% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 84.9% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 80.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.1% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 54% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.